Answers are grounded in this paper and cite their sources.
Objectives: Rheocarna ® therapy has recently been reported to improve peripherally measured blood flow as an adjuvant treatment after revascularization in patients with chronic limb-threatening ischemia. We investigated whether skin perfusion pressure and continuous walking distance were improved by performing Rheocarna ® therapy after distal bypass surgery. Methods: This study included 10 patients who underwent Rheocarna ® therapy after distal bypass surgery between June 2022 and March 2023. Rheocarna ® therapy was performed five times after distal bypass surgery, and the skin perfusion pressure and continuous walking distance after distal bypass surgery were compared with those after Rheocarna ® therapy. Results: The average age was 74.7 years, and nine patients (90%) were male. All patients were undergoing dialysis, with an average of 14.5 years of dialysis history. There were six patients (60%) with diabetes mellitus and five (50%) with hyperlipidemia. The ankle-brachial index was 0.62 ± 0.36 before distal bypass surgery and 0.936 ± 0.16 after Rheocarna ® therapy, indicating a significant increase ( p = 0.0117). Skin perfusion pressure dorsalis pedis was 71.5 ± 27.0 mmHg after Rheocarna ® therapy, showing a marked increase from the preoperative value ( p = 0.0020). Skin perfusion pressure planta pedis was 65.0 ± 26.3 mmHg after Rheocarna ® therapy, which was a significant increase from the preoperative value ( p = 0.0293). The continuous walking distance was 78.5 ± 102.7 m after the Rheocarna ® therapy, which was a significant increase from the preoperative value ( p = 0.0039). Conclusion: The skin perfusion pressure and continuous walking distance were significantly improved by Rheocarna ® therapy after distal bypass surgery.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: